Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 503 clinical trials
None
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

triple negative breast cancer
EGFR
carcinoma
carboplatin
invasive breast cancer
  • 17 views
  • 21 Jan, 2021
  • 1 location
None
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

being placed on a personally designed treatment trial can improve the responses in patients with newly diagnosed triple-negative breast cancer (TNBC). Testing the primary tumor biopsy for certain

neutrophil count
biomarker analysis
breast cancer
taxane
triple-negative breast cancer
  • 3 views
  • 31 May, 2021
  • 11 locations
None
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast

bladder cancer
squamous cell carcinoma
breast cancer
fallopian tube
estrogen
  • 612 views
  • 20 Oct, 2021
  • 93 locations
None
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.

human epidermal growth factor
breast cancer
biomarker analysis
epidermal growth factor receptor
palb2
  • 24 views
  • 23 Jan, 2021
  • 5 locations
None
NordicTrip a Translational Study of Preoperative Chemotherapy in TNBC

Primary aim: Pathological complete response rate after preoperative chemotherapy is the primary end-point of the study, which will be evaluated by comparing the effects of neoadjuvant administration of a carboplatin-based treatment and treatment adding capecitabine on Pathological Complete Response (pCR).

breast adenocarcinoma
BRCA2
carboplatin
capecitabine
cyclophosphamide
  • 5 views
  • 26 Jan, 2021
  • 35 locations
None
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); Arm B: treatment of physicians choice (TPC, defined as capecitabine or platinum-based chemotherapy …

  • 0 views
  • 26 Jan, 2021
  • 32 locations
None
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.

adjuvant chemotherapy
neutrophil count
estrogen
metastasis
serum total bilirubin
  • 315 views
  • 12 Aug, 2021
  • 129 locations
None
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of

axillary lymph node dissection
adjuvant chemotherapy
breast cancer
denosumab
ductal carcinoma in situ
  • 513 views
  • 24 Jan, 2021
  • 703 locations
None
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans, and will be in two parts. The primary purpose of the parts are: Dose Escalation: To …

squamous cell carcinoma
lung cancer
estrogen
solid tumour
endocrine therapy
  • 258 views
  • 10 Oct, 2021
  • 8 locations
None
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular …

metastasis
core needle biopsy
measurable disease
programmed cell death 1 ligand 1
solid tumour
  • 113 views
  • 28 Jun, 2021
  • 9 locations